T-cell redirection

T-cell redirection is a therapeutic strategy rather than a specific molecular target or receptor. It's an immunotherapy approach that uses engineered molecules to redirect T cells to recognize and attack cancer cells or pathogens. This strategy involves bispecific antibodies or similar constructs that bind to both T cells and target cells, creating an artificial immunological synapse that activates the T cell to attack the target cell. T-cell redirection represents a promising approach in immunotherapy that bypasses some limitations of conventional T-cell responses by creating artificial recognition and activation mechanisms against specific targets.

T-cell redirection is an immunotherapeutic strategy that uses engineered molecules, such as bispecific antibodies or T-cell engagers. These molecules have two binding domains: one binds to CD3 on T cells, and the other binds to a specific antigen on target cells (e.g., tumor cells). This creates a physical bridge between the T cell and the target cell, forming an artificial immunological synapse. This interaction leads to MHC-unrestricted activation of the T cell, prompting it to kill the target cell through direct delivery of cytotoxic proteases (cell contact-dependent killing), release of inflammatory cytokines (cytokine-mediated killing), and the formation of an immunological synapse.